Celcuity Launches REVTORPYK for Advanced Breast Cancer Treatment…

Event summary

REVTORPYK (gedatolisib) is now commercially available in the U.S. for HR+/HER2- advanced breast cancer patients without PIK3CA mutations.
The therapy reduced the risk of disease progression or death by 76% in the triplet combination and 67% in the doublet combination in the Phase 3 VIKTORIA-1 trial.
Celcuity has launched REVTORPYK Support Services to assist with patient access and financial assistance.
A supplemental New Drug Application for PIK3CA mutated patients was submitted to the FDA in August 2026.

The big picture

Celcuity's launch of REVTORPYK marks a significant advancement in targeted therapies for HR+/HER2- advanced breast cancer, addressing a critical unmet need in the second-line setting. The therapy's unique mechanism, inhibiting all class I PI3K isoforms and mTOR complexes, sets it apart from other treatments. The company's strategic focus on patient access and support services underscores its commitment to commercializing the therapy effectively. This launch positions Celcuity to capture a substantial share of the advanced breast cancer treatment market, which remains a high-priority area for biotech innovation.

What we're watching

Regulatory Approval: Whether the FDA will approve the supplemental New Drug Application for PIK3CA mutated patients, expanding REVTORPYK's market potential.
Market Penetration: The pace at which Celcuity can establish REVTORPYK as a standard treatment option in the HR+/HER2- advanced breast cancer space.
Competitive Dynamics: How REVTORPYK's comprehensive blockade of the PI3K/AKT/mTOR pathway will position it against existing and emerging therapies.